Please assess the completion status of the following clinical trial:

Trial Title: Optimizing IFN Beta - 1B Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained.~2. Age between 18 and 50 years inclusive.~3. Male and female patients.~4. Clinically definite or laboratory supported definite RR MS (Poser et al, 1983) for not less than 2 year.~5. Two clinically documented relapses during the preceding 24 months.~6. No relapse or relapse related neurological deterioration for at least 30 days prior to entry in the study.~7. Patients EDSS score from 1 to 3.5 (probably to be extended to 5.5).~8. MRI activity. At least one enhancing lesion during the baseline MRI run-in study .~9. Women capable of having children must agree to use adequate con-traceptive methods (condoms with spermicides, IUCD, oral contraceptives or other adequate barrier contraception).~10. Caregivers agreement to assist the patient to comply with study requirements, if neces-sary (e.g. study drug administration, visits to center).~Exclusion Criteria:~1. Any form of Multiple Sclerosis other than relapsing-remitting.~2. Any other disease which could better explain the patient's signs and symptoms.~3. Any other disabling condition, which could interfere with the clinical evaluation.~4. Pregnancy or lactation.~5. Medical psychiatric, or other conditions that compromise patient's ability to give informed consent, to comply with the trial protocol, or to complete the study.~6. Alcohol or drug abuse in the 90 days preceding screening visit.~7. Uncontrolled clinically significant heart diseases, i.e., cardiac arrhythmias, uncon-trolled angina pectoris, uncompensated congestive heart failure~8. Clinically significant liver, renal and bone marrow dysfunction as defined by the ran-ges of laboratory evaluations. The following ranges (see table 1) for key laboratory evaluations will be considered as adequate for inclusion:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).